Adriano Lazzarin

语言:
EN
IT
FR

个人简介

Adriano Lazzarin教授是圣拉斐尔生命健康大学荣誉教授、IRCCS圣拉斐尔科学研究医院Turro分院传染病科顾问,同时就职于米兰Casa di Cura La Madonnina医院。

1970年,Lazzarin教授毕业于米兰大学医学院,自此开始了他的研究生涯。Lazzarin教授在热那亚大学主修内分泌学(1974年),在米兰大学先后获得了内科(1979年)和传染病(1982年)方向的专业学位。

自1987年起,Lazzarin教授一直在多个HIV和肝炎研究小组担任主要研究者和协调研究者。他荣获了欧洲临床艾滋病学会(EACS)颁发的“HIV医学卓越成就”奖,并且是意大利国内外多个卫生委员会的成员。

Lazzarin教授在New England Journal of Medicine、The Lancet、Blood、Nature、Hepatology、AIDS、Journal of Infectious Diseases、Clinical Infectious Diseases、Science、Annals of Internal Medicine、Annals of Oncology、Journal of NeurologyJournal of Acquired Immune Deficiency Syndromes等期刊上发表了800多篇科研论文。

教育背景

米兰大学
医学博士学位 - 1970年

米兰大学
内分泌科高等学院 - 1974年

米兰大学
内科研究生院 - 1979年

米兰大学
传染病科高等学院 - 1982年

多媒体中心

您需要预约吗?

联系我们,我们将为您妥善安排。

出版物

最新出版物

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet. 2007 Jul 7;370(9581):39-48. PubMed PMID: 17617271.
Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., Moll A., Towner W., Trottier B., Peeters M., Vingerhoets J., de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group.
扩展阅读
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).
AIDS. 2006 Apr 4;20(6):795-803. PubMed PMID: 16549962.
Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A.
扩展阅读
Mutations and Salvage (MuSa) Study Group. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.
Clin Infect Dis. 2006 May 15;42(10):1470-80. Epub 2006 Apr 13. PubMed PMID: 16619162.
Gianotti N., Mondino V., Rossi MC., Chiesa E., Mezzaroma I., Ladisa N., Guaraldi G., Torti C., Tarquini P., Castelli P., Di Carlo A., Boeri E., Keulen W., Kenna PM, Lazzarin A.;
扩展阅读
TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
N Engl J Med. 2003. May 29;348(22):2186-95. PubMed PMID: 12773645.
Lazzarin A., Clotet B., Cooper D., Reynes J., Arastéh K., Nelson M., Katlama C., Stellbrink HJ, Delfraissy JF, Lange J., Huson L., DeMasi R., Wat C, Delehanty J., Drobnes C., Salgo M.;
扩展阅读
Efficacy of low-dose intermittent subcutaneous interleukin (IL)—2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
J Infect Dis. 2001 May 15;183(10):1476-84. Epub 2001 Apr 13. PubMed PMID: 11319683.
Tambussi G., Ghezzi S., Nozza S., Vallanti G., Magenta L., Guffanti M., Brambilla A., Vicenzi E., Carrera P., Racca S., Soldini L., Gianotti N., Murone M., Veglia F., Poli G., Lazzarin A.
扩展阅读
Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients.
AIDS. 1999 Jan 14;13(1):140-1. PubMed PMID: 10207560.
Uberti-Foppa C, De Bona A, Morsica G, Guffanti M, Gianotti N, Boeri E, Lazzarin A.
扩展阅读
Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction.
AIDS. 1997 Jan;11(1):1-17. Review. PubMed PMID: 9110070.
Cinque P., Scarpellini P., Vago L., Linde A., Lazzarin A.
扩展阅读
Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome.
AIDS. 1996 Nov;10(13):F45-50. PubMed PMID: 8931778.
Rizzardi GP, Barcellini W., Tambussi G., Lillo F., Malnati M., Perrin L., Lazzarin A.
扩展阅读
Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study.
Am J Epidemiol. 1992 Feb 1;135(3):225-33. PubMed PMID: 1312300.
Nicolosi A., Leite ML, Musicco M., Molinari S., Lazzarin A.
扩展阅读

您需要预约吗?

联系我们,我们将为您妥善安排。